NEW YORK (Reuters) -Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying kickbacks to doctors who agreed to prescribe its HIV drugs, the U.S. attorney’s office in Manhattan said on Tuesday.
The settlement resolves claims that Gilead paid honoraria, meals and travel expenses to doctors who attended Gilead speaker events to induce them to prescribe several HIV drugs.
U.S. Attorney Jay Clayton said this violated the federal False Claims Act by causing claims to be paid by federal healthcare programs.
(Reporting by Jonathan Stempel in New York; Editing by Chris Reese)
Comments